Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash & Current Investments (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Cash & Current Investments data on record, last reported at $800.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 1095.35% year-over-year to $800.1 million; the TTM value through Dec 2025 reached $800.1 million, up 1095.35%, while the annual FY2025 figure was $800.1 million, 1095.35% up from the prior year.
  • Cash & Current Investments reached $800.1 million in Q4 2025 per CAI's latest filing, up from $757.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $800.1 million in Q4 2025 and bottomed at $66.9 million in Q4 2024.